These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 35917107)

  • 21. Tuning Responses to Polatuzumab Vedotin in B-cell Lymphoma.
    Leveille E; Kothari S; Cosgun KN; Mlynarczyk C; Müschen M
    Cancer Discov; 2024 Sep; 14(9):1577-1580. PubMed ID: 39228298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polatuzumab vedotin combined with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma: A systematic review protocol.
    Eslami M; Mehrabi M; Payandeh M; Saba F
    PLoS One; 2024; 19(8):e0308247. PubMed ID: 39088571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polatuzumab vedotin in relapsed / refractory aggressive B-cell lymphoma.
    Varma G; Wang J; Diefenbach C
    Expert Rev Anticancer Ther; 2022 Aug; 22(8):795-803. PubMed ID: 35726803
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Spotlight on polatuzumab vedotin: new standards for diffuse large B-cell lymphoma?
    Ghione P; Salles G
    Haematologica; 2024 Sep; 109(9):2802-2809. PubMed ID: 38813707
    [TBL] [Abstract][Full Text] [Related]  

  • 25. US cost-effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma.
    Betts KA; Thuresson PO; Felizzi F; Du EX; Dieye I; Li J; Schulz M; Masaquel AS
    J Comp Eff Res; 2020 Oct; 9(14):1003-1015. PubMed ID: 33028076
    [No Abstract]   [Full Text] [Related]  

  • 26. Refractory hemophagocytic lymphohistiocytosis secondary to polatuzumab vedotin plus rituximab and bendamustine.
    Lv K; Kong F; Yu M; Zhou Y; Li F
    Ann Hematol; 2024 Mar; 103(3):1017-1019. PubMed ID: 38155243
    [No Abstract]   [Full Text] [Related]  

  • 27. Treatment strategies for patients with diffuse large B-cell lymphoma.
    Poletto S; Novo M; Paruzzo L; Frascione PMM; Vitolo U
    Cancer Treat Rev; 2022 Nov; 110():102443. PubMed ID: 35933930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polatuzumab vedotin pharmacokinetics in a hemodialysis patient with diffuse large B-cell lymphoma.
    Yasuda H; Kaga N; Taka H; Ochiai T; Yamana T; Miura Y; Ishii M; Sasaki M; Ando J; Ando M
    Cancer Chemother Pharmacol; 2024 Mar; 93(3):265-268. PubMed ID: 37750932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy.
    Gouni S; Rosenthal AC; Crombie JL; Ip A; Kamdar MK; Hess B; Feng L; Watson G; Ayers A; Neelapu SS; Khurana A; Lin Y; Iqbal M; Merryman RW; Strati P
    Blood Adv; 2022 May; 6(9):2757-2762. PubMed ID: 35240681
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation and use of an anti-cynomolgus monkey CD79b surrogate antibody-drug conjugate to enable clinical development of polatuzumab vedotin.
    Li D; Lee D; Dere RC; Zheng B; Yu SF; Fuh FK; Kozak KR; Chung S; Bumbaca Yadav D; Nazzal D; Danilenko D; Go MAT; Williams M; Polson AG; Poon KA; Prabhu S
    Br J Pharmacol; 2019 Oct; 176(19):3805-3818. PubMed ID: 31270798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas.
    Dimou M; Papageorgiou SG; Stavroyianni N; Katodritou E; Tsirogianni M; Kalpadakis C; Banti A; Arapaki M; Iliakis T; Bouzani M; Verrou E; Spanoudakis E; Giannouli S; Marinakis T; Mandala E; Mparmparousi D; Sachanas S; Dalekou-Tsolakou M; Hatzimichael E; Vadikolia C; Violaki V; Poziopoulos C; Tsirkinidis P; Chatzileontiadou S; Vervessou E; Ximeri M; Sioni A; Konstantinidou P; Kyrtsonis MC; Siakantaris MP; Angelopoulou MK; Pappa V; Konstantopoulos K; Panayiotidis P; Vassilakopoulos TP
    Hematol Oncol; 2021 Aug; 39(3):336-348. PubMed ID: 33583077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polatuzumab Vedotin: First Global Approval.
    Deeks ED
    Drugs; 2019 Sep; 79(13):1467-1475. PubMed ID: 31352604
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study.
    Flowers CR; Matasar MJ; Herrera AF; Hertzberg M; Assouline S; Demeter J; McMillan A; Mehta A; Opat S; Trnňný M; Musick L; Hirata J; Yang A; Sehn LH
    Haematologica; 2024 Apr; 109(4):1194-1205. PubMed ID: 37767550
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody-drug conjugates for previously treated aggressive lymphomas: focus on polatuzumab vedotin.
    Burke JM; Morschhauser F; Andorsky D; Lee C; Sharman JP
    Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1073-1083. PubMed ID: 32985934
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world.
    Vodicka P; Benesova K; Janikova A; Prochazka V; Belada D; Mocikova H; Steinerova K; Duras J; Karban J; Hanackova V; Sykorova A; Obr A; Trneny M
    Eur J Haematol; 2022 Aug; 109(2):162-165. PubMed ID: 35502609
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical pharmacology strategies to accelerate the development of polatuzumab vedotin and summary of key findings.
    Liao MZ; Lu D; Lu T; Gibiansky L; Deng R; Samineni D; Dere R; Lin A; Hirata J; Shen BQ; Zhang D; Li D; Li C; Miles D
    Adv Drug Deliv Rev; 2024 Apr; 207():115193. PubMed ID: 38311111
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma.
    Patel KK; Isufi I; Kothari S; Foss F; Huntington S
    Leuk Lymphoma; 2020 Dec; 61(14):3387-3394. PubMed ID: 32835553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Nowakowski GS; Yoon DH; Mondello P; Joffe E; Peters A; Fleury I; Greil R; Ku M; Marks R; Kim K; Zinzani PL; Trotman J; Sabatelli L; Waltl EE; Winderlich M; Sporchia A; Kurukulasuriya NC; Cordoba R; Hess G; Salles G
    Ann Hematol; 2023 Jul; 102(7):1773-1787. PubMed ID: 37171597
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience.
    Wang YW; Tsai XC; Hou HA; Tien FM; Liu JH; Chou WC; Ko BS; Chen YW; Lin CC; Cheng CL; Lo MY; Lin YC; Lu LC; Wu SJ; Kuo SH; Hong RL; Huang TC; Yao M
    Ann Hematol; 2022 Feb; 101(2):349-358. PubMed ID: 34766217
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Successful polatuzumab vedotin and rituximab therapy for post-CAR-T relapse of diffuse large B-cell lymphoma].
    Kushida T; Hirosawa M; Goto M; Seike Y; Kitamura N; Nakanishi T; Tanaka A; Higashi T; Morimoto H; Tsukada J
    Rinsho Ketsueki; 2024; 65(3):180-182. PubMed ID: 38569863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.